Andrew Davis
Corporate Officer/Principal presso IRONWOOD PHARMACEUTICALS, INC.
Patrimonio netto: 2 M $ in data 31/05/2024
Profilo
Andrew Davis is currently the Director at UTILITY therapeutics Ltd.
and the SVP-Corporate Development, Strategy & Valuation at Ironwood Pharmaceuticals, Inc. Previously, he served as the Chairman at VectivBio Holding AG, Director at BioMarck Pharmaceuticals Ltd., Senior Vice President-Business Development at Bausch Health US LLC, Vice President-Corporate Development at Bausch Health Cos., Inc., Chief Business Development Officer at iNova Pharmaceuticals (Pty) Ltd.
(South Africa), and Head-Oncology Business Development at Merck & Co., Inc. He obtained his undergraduate degree from Boston University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
20/05/2024 | 288 031 ( 0.18% ) | 2 M $ | 31/05/2024 |
Posizioni attive di Andrew Davis
Società | Posizione | Inizio |
---|---|---|
IRONWOOD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/05/2021 |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Direttore/Membro del Consiglio | 01/08/2019 |
Precedenti posizioni note di Andrew Davis
Società | Posizione | Fine |
---|---|---|
BioMarck Pharmaceuticals Ltd.
BioMarck Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology BioMarck Pharmaceuticals Ltd. engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders. It develops its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. The company was founded by Indu Parikh, Allen F. Gant, Thomas H. Roberg and Kenneth Adl in 2002 and is headquartered in Durham, NC. | Direttore/Membro del Consiglio | 01/10/2022 |
iNova Pharmaceuticals (Pty) Ltd. (South Africa)
iNova Pharmaceuticals (Pty) Ltd. (South Africa) Pharmaceuticals: MajorHealth Technology Part of iNova Pharmaceuticals (Australia) Pty Ltd., iNova Pharmaceuticals (Pty) Ltd. is a South African company that develops and markets a range of healthcare products. The company is based in Bedfordview, South Africa. The company's products include B-CAL-K2, a calcium and bone health supplement with clinically proven K2, and PregOmega Plus, a multivitamin and mineral supplement for pregnancy. The company is committed to promoting and manufacturing quality products that bring real benefits and comply with Good Manufacturing Practices (GMP). | Corporate Officer/Principal | 01/05/2021 |
MERCK & CO., INC. | Corporate Officer/Principal | 01/09/2017 |
Bausch Health US LLC
Bausch Health US LLC Pharmaceuticals: MajorHealth Technology Bausch Health US LLC engages in the development, manufacture and market of pharmaceutical products. It specializes in therapeutic areas of neurology, dermatology, and infectious diseases. The company was founded in 2001 and is headquartered in Raleigh, NC. | Corporate Officer/Principal | 01/01/2016 |
VECTIVBIO HOLDING AG | Presidente | - |
Formazione di Andrew Davis
Boston University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
BAUSCH HEALTH COMPANIES INC. | Health Technology |
Aziende private | 5 |
---|---|
BioMarck Pharmaceuticals Ltd.
BioMarck Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology BioMarck Pharmaceuticals Ltd. engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders. It develops its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. The company was founded by Indu Parikh, Allen F. Gant, Thomas H. Roberg and Kenneth Adl in 2002 and is headquartered in Durham, NC. | Health Technology |
Bausch Health US LLC
Bausch Health US LLC Pharmaceuticals: MajorHealth Technology Bausch Health US LLC engages in the development, manufacture and market of pharmaceutical products. It specializes in therapeutic areas of neurology, dermatology, and infectious diseases. The company was founded in 2001 and is headquartered in Raleigh, NC. | Health Technology |
iNova Pharmaceuticals (Pty) Ltd. (South Africa)
iNova Pharmaceuticals (Pty) Ltd. (South Africa) Pharmaceuticals: MajorHealth Technology Part of iNova Pharmaceuticals (Australia) Pty Ltd., iNova Pharmaceuticals (Pty) Ltd. is a South African company that develops and markets a range of healthcare products. The company is based in Bedfordview, South Africa. The company's products include B-CAL-K2, a calcium and bone health supplement with clinically proven K2, and PregOmega Plus, a multivitamin and mineral supplement for pregnancy. The company is committed to promoting and manufacturing quality products that bring real benefits and comply with Good Manufacturing Practices (GMP). | Health Technology |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Health Technology |
VectivBio Holding AG
VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
- Borsa valori
- Insiders
- Andrew Davis